98%
921
2 minutes
20
Objective: This study aimed to evaluate the predictive efficacy of combining serum soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio with uterine artery Doppler ultrasound for early-onset preeclampsia (PE) before 34 weeks' gestation.
Methods: A retrospective cohort analysis was conducted on 148 singleton pregnancies (control group: n = 76; early-onset PE group: n = 72) who delivered at our institution between July 2023 and June 2024. At 24-28 weeks, serum sFlt-1 and PlGF levels were quantified via electrochemiluminescence immunoassay (Roche Elecsys), and uterine artery pulsatility index (PI), resistance index (RI), and systolic/diastolic ratio (S/D) were measured by Doppler ultrasound (M22 system, standardized settings). Logistic regression and receiver operating characteristic (ROC) curves assessed predictive performance.
Results: Compared to controls, PE patients exhibited significantly elevated sFlt-1 (24.02 ± 6.68 vs 16.38 ± 7.47 μg/L; P < 0.001), reduced PlGF (1.22 ± 0.14 vs 1.54 ± 0.30 μg/L; P < 0.001), and higher sFlt-1/PlGF ratio (20.76 ± 7.71 vs 10.11 ± 4.10; P < 0.001). Doppler indices were markedly increased in PE: PI (1.34 ± 0.26 vs 0.82 ± 0.11; P < 0.001), RI (0.78 ± 0.12 vs 0.51 ± 0.07; P < 0.001), and S/D (3.89 ± 0.97 vs 2.11 ± 0.41; P < 0.001). Multivariate analysis confirmed all parameters as independent predictors (P < 0.05), with sFlt-1/PlGF ratio having the highest odds ratio (OR = 1.332, 95% CI: 1.128-1.573). The combined model achieved superior predictive performance: area under curve (AUC)=0.954 (95% CI: 0.92-0.99) vs sFlt-1/PlGF alone (AUC = 0.887; P = 0.003) or PI alone (AUC = 0.821; P < 0.001), with sensitivity 82.2%, specificity 96.7%, and accuracy 94.7%.
Conclusion: Integration of sFlt-1/PlGF ratio and uterine artery Doppler parameters (particularly uterine artery PI and RI) significantly enhances early-onset PE prediction, providing a robust tool for clinical risk stratification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363554 | PMC |
http://dx.doi.org/10.2147/IJWH.S539946 | DOI Listing |
Radiography (Lond)
September 2025
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta. Electronic address:
Introduction: Threatened miscarriage (TM), defined as first-trimester vaginal bleeding with a closed cervix and detectable fetal cardiac activity, affects up to 30 % of clinically recognised pregnancies and is linked to increased risk of adverse outcomes. This study evaluates the predictive value of first-trimester ultrasound (US) and biochemical (BC) markers in determining outcomes among women with TM symptoms.
Methods: This prospective cohort study recruited 118 women with viable singleton pregnancies (5 to 12 weeks' gestation) from Malta's national public hospital between January 2023 and June 2024.
Int J Womens Health
August 2025
Obstetrics Department, the Second Affiliated Hospital of Shandong First Medical University, Tai 'an, Shandong, 271000, People's Republic of China.
Objective: This study aimed to evaluate the predictive efficacy of combining serum soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio with uterine artery Doppler ultrasound for early-onset preeclampsia (PE) before 34 weeks' gestation.
Methods: A retrospective cohort analysis was conducted on 148 singleton pregnancies (control group: n = 76; early-onset PE group: n = 72) who delivered at our institution between July 2023 and June 2024. At 24-28 weeks, serum sFlt-1 and PlGF levels were quantified via electrochemiluminescence immunoassay (Roche Elecsys), and uterine artery pulsatility index (PI), resistance index (RI), and systolic/diastolic ratio (S/D) were measured by Doppler ultrasound (M22 system, standardized settings).
Fetal Diagn Ther
August 2025
Introduction: This study aimed to identify a cutoff value for the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio to predict adverse outcomes in early-onset fetal growth restriction (FGR).
Methods: In this single-center, non-blinded, retrospective cohort study, maternal serum sFlt-1/PlGF ratios were measured at the time of early-onset FGR diagnosis (<34 weeks) using Roche Elecsys® assays. The optimal cutoff for predicting severe adverse outcomes within 2 weeks was determined using receiver operating characteristic analysis.
medRxiv
July 2025
Division of Maternal Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Objective: We investigated the independent and comparative association of a history of hypertensive disease of pregnancy and elevated serum soluble fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) ratio during the second half of pregnancy with the development of HTN up to 15 years after delivery.
Study Design: N=1,238 singleton pregnancies were part of a prospective birth cohort study that enrolled patients from 2006-2008. Serum sFlt-1/PlGF was collected at a median of 26.
Hypertens Res
August 2025
Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Obstetric care in Japan is organized in 3 levels and half of all deliveries are conducted at primary facilities without neonatal intensive care unit. We evaluated the predictive accuracy of the sFlt-1/PlGF ratio for the onset of preeclampsia and adverse outcomes in pregnant women with suspected preeclampsia at multiple facilities in Japan, including primary facilities. 356 pregnant women from 18 + 0 to 36 + 6 weeks of pregnancy were enrolled.
View Article and Find Full Text PDF